
MLYS Stock Forecast & Price Target
MLYS Analyst Ratings
Bulls say
Mineralys Therapeutics Inc. has garnered positive feedback based on its lead product candidate, lorundrostat, which demonstrates a significant placebo-adjusted blood pressure benefit exceeding 10 mmHg, making it a promising option for patients with uncontrolled and resistant hypertension. The company has established a differentiated profile for lorundrostat, supported by robust data from the Advance-HTN trial and anticipated feedback from the FDA, potentially positioning the candidate favorably within the biopharmaceutical market. Furthermore, the increase in the estimated percentage of patients seeking novel treatments from 10% to 12% amongst diagnosed uncontrolled hypertension patients indicates a growing unmet need that could drive future demand for lorundrostat.
Bears say
The negative outlook on Mineralys Therapeutics's stock is primarily driven by concerns regarding the company's ability to achieve projected peak commercial revenue for its product candidate, lorundrostat, which could be hindered by factors such as market size, penetration rates, and pricing strategies. Additionally, potential challenges in securing necessary capital resources to fund operations pose a significant risk, further complicating the company’s developmental and commercialization efforts. Furthermore, there are clinical considerations related to the drug's safety profile, specifically the management of hyperkalemia, which could impact patient uptake and acceptance in the market.
This aggregate rating is based on analysts' research of Mineralys Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
MLYS Analyst Forecast & Price Prediction
Start investing in MLYS
Order type
Buy in
Order amount
Est. shares
0 shares